ArticleBMC urology2019
Efficacy and safety of botulinum toxin a injection into urethral sphincter for underactive bladder.
Article in BMC urology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
8 citing papers in PubMed, 10 citations in OpenAlex.
- Predictors of successful outcomes of urethral sphincter botox injection in women with non-neurogenic voiding dysfunction.International urology and nephrology · 2026Article
- A Potential Urodynamic Classification of Voiding Patterns in Neurogenic Lower Urinary Tract Dysfunction Due to Lower-Level Spinal Cord Injury.Journal of clinical medicine · 2026Article
- Clinical efficacy and urodynamic predictors of successful treatment outcomes following urethral sphincter botulinum toxin A injection in women with non-spinal cord neurogenic voiding dysfunction.International urology and nephrology · 2026Article
- Long-term Outcomes of Periurethral Sphincter Botulinum Toxin in Female Chronic Urinary Retention.International neurourology journal · 2024Article
- Article
- Article
- Detrusor Underactivity in Men with Bladder Outlet Obstruction.Biomedicines · 2022Review
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe aim of this retrospective study was to evaluate the clinical efficacy and safety of botulinum toxin type A (BTX-A) injection into the urethral sphincter to treat patients with underactive bladder (UAB).
methodsFrom September 2012 to December 2018, 35 patients with UAB who presented with dysuria were treated with BTX-A (Prosigne®, Lanzhou Biological Products, Lanzhou, China). All patients were evaluated using the International Continence Society standard for video-urodynamic examination before and 1 month after treatment. The index includes maximum urinary flow rate, detrusor leak point pressure, and maximum urethral pressure. Post-voiding residual urine volume was measured using ultrasound before, one and 3 months post injection.
resultsAfter 1 month of treatment, the maximum flow rate increased from 2.5 ± 1.1 ml/s to 6.6 ± 1.7 ml/s (P < 0. 05). The maximum urethral pressure decreased from 73.5 ± 5.8 cmH
conclusionsThe results suggest that Prosigne® injection into the urethral sphincter is an effective, safe, and inexpensive way to treat UAB.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.